前列腺癌诊断技术的研究进展
Research Advances in Diagnostic Techniques for Prostate Cancer
DOI: 10.12677/acm.2026.1631027, PDF,   
作者: 李良宇*, 徐光勇#：重庆医科大学附属第二医院泌尿外科，重庆
关键词: 前列腺癌；前列腺特异性膜抗原；Prostate Cancer； Prostate-Specific Membrane Antigen
摘要: 前列腺癌是全世界第二常见的男性恶性肿瘤疾病。前列腺癌早期多因无显著临床表现而很难被发现。目前对前列腺癌的诊断主要依赖于直肠指检、前列腺特异性抗原检测、经直肠超声检查、多参数磁共振成像、前列腺特异性膜抗原正电子发射断层扫描。早期、准确诊断前列腺癌并予以及时治疗，能够增加患者生存率。本综述对前列腺癌各种诊断方法研究进展进行综述，供临床参考。
Abstract: Prostate cancer is the second most common male malignant disease worldwide. Prostate cancer is difficult to detect in the early stage because of the lack of significant clinical manifestations. At present, the diagnosis of prostate cancer mainly relies on digital rectal examination, prostate specific antigen detection, transrectal ultrasonography, multi-parametric magnetic resonance imaging, and prostate specific membrane antigen positron emission tomography. Early and accurate diagnosis of prostate cancer and timely treatment can improve the survival rate of patients. This article reviews the research progress of various diagnostic methods for prostate cancer for clinical reference.
文章引用：李良宇, 徐光勇. 前列腺癌诊断技术的研究进展[J]. 临床医学进展, 2026, 16(3): 2320-2326. https://doi.org/10.12677/acm.2026.1631027

参考文献

[1] Rebello, R.J., Oing, C., Knudsen, K.E., Loeb, S., Johnson, D.C., Reiter, R.E., et al. (2021) Prostate Cancer. Nature Reviews Disease Primers, 7, Article No. 9. [Google Scholar] [CrossRef] [PubMed]
[2] 前列腺癌筛查中国专家共识(2021年版) [J]. 中国癌症杂志, 2021, 31(5): 435-440.
[3] Ying, Y., He, W., Xiong, Q., Wang, Z., Wang, M., Chen, Q., et al. (2023) Value of Digital Rectal Examination in Patients with Suspected Prostate Cancer: A Prospective Cohort Analysis Study. Translational Andrology and Urology, 12, 1666-1672. [Google Scholar] [CrossRef] [PubMed]
[4] Mottet, N., van den Bergh, R.C.N., Briers, E., Van den Broeck, T., Cumberbatch, M.G., De Santis, M., et al. (2021) EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer—2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. European Urology, 79, 243-262. [Google Scholar] [CrossRef] [PubMed]
[5] Oesterling, J.E. (1991) Prostate Specific Antigen: A Critical Assessment of the Most Useful Tumor Marker for Adenocarcinoma of the Prostate. Journal of Urology, 145, 907-923. [Google Scholar] [CrossRef] [PubMed]
[6] Sekhoacha, M., Riet, K., Motloung, P., Gumenku, L., Adegoke, A. and Mashele, S. (2022) Prostate Cancer Review: Genetics, Diagnosis, Treatment Options, and Alternative Approaches. Molecules, 27, Article No. 5730. [Google Scholar] [CrossRef] [PubMed]
[7] Ferraro, S., Bussetti, M. and Panteghini, M. (2021) Serum Prostate-Specific Antigen Testing for Early Detection of Prostate Cancer: Managing the Gap between Clinical and Laboratory Practice. Clinical Chemistry, 67, 602-609. [Google Scholar] [CrossRef] [PubMed]
[8] Ahamed, Y., Hossain, M., Baral, S., Al-Raiyan, A.U., Ashraf, S.B. and Sun, W. (2025) The Research Progress on Diagnostic Indicators Related to Prostate-Specific Antigen Gray-Zone Prostate Cancer. BMC Cancer, 25, Article No. 1264. [Google Scholar] [CrossRef] [PubMed]
[9] Wang, C., Wang, Y., Wang, S., Ding, J., Ding, M., Ruan, Y., et al. (2021) Peripheral Zone PSA Density: A Predominant Variable to Improve Prostate Cancer Detection Efficiency in Men with PSA Higher than 4 ng ml(−1). Asian Journal of Andrology, 23, 415-420. [Google Scholar] [CrossRef] [PubMed]
[10] Loeb, S., Sanda, M.G., Broyles, D.L., Shin, S.S., Bangma, C.H., Wei, J.T., et al. (2015) The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. Journal of Urology, 193, 1163-1169. [Google Scholar] [CrossRef] [PubMed]
[11] Bruzzese, D., Mazzarella, C., Ferro, M., Perdonà, S., Chiodini, P., Perruolo, G., et al. (2014) Prostate Health Index vs Percent Free Prostate-Specific Antigen for Prostate Cancer Detection in Men with “Gray” Prostate-Specific Antigen Levels at First Biopsy: Systematic Review and Meta-Analysis. Translational Research, 164, 444-451. [Google Scholar] [CrossRef] [PubMed]
[12] 张明博, 罗渝昆, 张艳, 等. 经直肠多模态超声影像评分系统诊断前列腺癌的临床研究[J]. 中华医学超声杂志(电子版), 2019, 16(1): 66-71.
[13] Ganie, F.A., Wanie, M.S., Ganie, S.A., Lone, H., Gani, M., Mir, M.F., et al. (2014) Correlation of Transrectal Ultrasonographic Findings with Histo Pathology in Prostatic Cancer. Journal of Education and Health Promotion, 3, Article No. 38. [Google Scholar] [CrossRef] [PubMed]
[14] Matsumoto, K., Nakagawa, K., Hashiguchi, A., Kono, H., Kikuchi, E., Nagata, H., et al. (2010) Contrast-Enhanced Ultrasonography of the Prostate with Sonazoid. Japanese Journal of Clinical Oncology, 40, 1099-1104. [Google Scholar] [CrossRef] [PubMed]
[15] Li, H., Xia, J., Xie, S., Guo, Y., Xin, M. and Li, F. (2015) Prostate Cancer: A Comparison of the Diagnostic Performance of Transrectal Ultra-Sound versus Contrast Enhanced Transrectal Ultrasound in Different Clinical Characteristics. International Journal of Clinical and Experimental Medicine, 8, 21428-21434.
[16] van Hove, A., Savoie, P., Maurin, C., Brunelle, S., Gravis, G., Salem, N., et al. (2014) Comparison of Image-Guided Targeted Biopsies versus Systematic Randomized Biopsies in the Detection of Prostate Cancer: A Systematic Literature Review of Well-Designed Studies. World Journal of Urology, 32, 847-858. [Google Scholar] [CrossRef] [PubMed]
[17] Inoue, T. and Shin, T. (2023) Current Magnetic Resonance Imaging‐Based Diagnostic Strategies for Prostate Cancer. International Journal of Urology, 30, 1078-1086. [Google Scholar] [CrossRef] [PubMed]
[18] O’Connor, L., Wang, A., Walker, S.M., Yerram, N., Pinto, P.A. and Turkbey, B. (2020) Use of Multiparametric Magnetic Resonance Imaging (mpMRI) in Localized Prostate Cancer. Expert Review of Medical Devices, 17, 435-442. [Google Scholar] [CrossRef] [PubMed]
[19] Lorusso, V., Talso, M., Palmisano, F., Branger, N., Granata, A.M., Fiori, C., et al. (2024) Is Imaging Accurate Enough to Detect Index Lesion in Prostate Cancer? Analysis of the Performance of MRI and Other Imaging Modalities. Minerva Urology and Nephrology, 76, 22-30. [Google Scholar] [CrossRef] [PubMed]
[20] Fazekas, T., Pallauf, M., Kufel, J., Miszczyk, M., Tsuboi, I., Matsukawa, A., et al. (2025) Molecular Correlates of Prostate Cancer Visibility on Multiparametric Magnetic Resonance Imaging: A Systematic Review. European Urology Oncology, 8, 1352-1364. [Google Scholar] [CrossRef] [PubMed]
[21] Ploussard, G., Rouvière, O., Rouprêt, M., van den Bergh, R. and Renard-Penna, R. (2022) The Current Role of MRI for Guiding Active Surveillance in Prostate Cancer. Nature Reviews Urology, 19, 357-365. [Google Scholar] [CrossRef] [PubMed]
[22] Greenberg, J.W., Koller, C.R., Lightfoot, C., Brinkley, G.J., Leinwand, G., Wang, J., et al. (2024) Annual mpMRI Surveillance: PI-RADS Upgrading and Increasing Trend Correlated with Patients Who Harbor Clinically Significant Disease. Urologic Oncology: Seminars and Original Investigations, 42, 158.e11-158.e16. [Google Scholar] [CrossRef] [PubMed]
[23] Luiting, H.B., Remmers, S., Boevé, E.R., Valdagni, R., Chiu, P.K., Semjonow, A., et al. (2022) A Multivariable Approach Using Magnetic Resonance Imaging to Avoid a Protocol-Based Prostate Biopsy in Men on Active Surveillance for Prostate Cancer—Data from the International Multicenter Prospective PRIAS Study. European Urology Oncology, 5, 651-658. [Google Scholar] [CrossRef] [PubMed]
[24] Valerio, M., Donaldson, I., Emberton, M., Ehdaie, B., Hadaschik, B.A., Marks, L.S., et al. (2015) Detection of Clinically Significant Prostate Cancer Using Magnetic Resonance Imaging-Ultrasound Fusion Targeted Biopsy: A Systematic Review. European Urology, 68, 8-19. [Google Scholar] [CrossRef] [PubMed]
[25] Afshar-Oromieh, A., Malcher, A., Eder, M., Eisenhut, M., Linhart, H.G., Hadaschik, B.A., et al. (2012) PET Imaging with a [68Ga]gallium-Labelled PSMA Ligand for the Diagnosis of Prostate Cancer: Biodistribution in Humans and First Evaluation of Tumour Lesions. European Journal of Nuclear Medicine and Molecular Imaging, 40, 486-495. [Google Scholar] [CrossRef] [PubMed]
[26] Combes, A.D., Palma, C.A., Calopedos, R., Wen, L., Woo, H., Fulham, M., et al. (2022) PSMA PET-CT in the Diagnosis and Staging of Prostate Cancer. Diagnostics, 12, Article No. 2594. [Google Scholar] [CrossRef] [PubMed]
[27] Satapathy, S., Singh, H., Kumar, R. and Mittal, B.R. (2021) Diagnostic Accuracy of 68Ga-PSMA PET/CT for Initial Detection in Patients with Suspected Prostate Cancer: A Systematic Review and Meta-Analysis. American Journal of Roentgenology, 216, 599-607. [Google Scholar] [CrossRef] [PubMed]
[28] Donato, P., Morton, A., Yaxley, J., Ranasinghe, S., Teloken, P.E., Kyle, S., et al. (2020) (68)Ga-PSMA PET/CT Better Characterises Localised Prostate Cancer after MRI and Transperineal Prostate Biopsy: Is (68)Ga-PSMA PET/CT Guided Biopsy the Future? European Journal of Nuclear Medicine and Molecular Imaging, 47, 1843-1851. [Google Scholar] [CrossRef] [PubMed]
[29] Scheltema, M.J., Chang, J.I., Stricker, P.D., van Leeuwen, P.J., Nguyen, Q.A., Ho, B., et al. (2019) Diagnostic Accuracy of 68Ga-Prostate-Specific Membrane Antigen (PSMA) Positron‐Emission Tomography (PET) and Multiparametric (mp)MRI to Detect Intermediate‐Grade Intra‐Prostatic Prostate Cancer Using Whole‐Mount Pathology: Impact of the Addition of 68Ga‐PSMA PET to mpMRI. BJU International, 124, 42-49. [Google Scholar] [CrossRef] [PubMed]
[30] Emmett, L., Buteau, J., Papa, N., Moon, D., Thompson, J., Roberts, M.J., et al. (2021) The Additive Diagnostic Value of Prostate-Specific Membrane Antigen Positron Emission Tomography Computed Tomography to Multiparametric Magnetic Resonance Imaging Triage in the Diagnosis of Prostate Cancer (PRIMARY): A Prospective Multicentre Study. European Urology, 80, 682-689. [Google Scholar] [CrossRef] [PubMed]
[31] Emmett, L.M., Papa, N., Buteau, J., Ho, B., Liu, V., Roberts, M., et al. (2022) The PRIMARY Score: Using Intra-Prostatic (68)Ga-PSMA PET/CT Patterns to Optimise Prostate Cancer Diagnosis. Journal of Nuclear Medicine, 63, 1644-1650. [Google Scholar] [CrossRef] [PubMed]
[32] Seifert, R., Emmett, L., Rowe, S.P., Herrmann, K., Hadaschik, B., Calais, J., et al. (2023) Second Version of the Prostate Cancer Molecular Imaging Standardized Evaluation Framework Including Response Evaluation for Clinical Trials (PROMISE V2). European Urology, 83, 405-412. [Google Scholar] [CrossRef] [PubMed]
[33] Shi, J., Li, D., Chen, M., Fu, Y., Peng, S., Zhang, Q., et al. (2024) The Value of 68Ga-PSMA PET/MRI for Classifying Patients with PI-RADS 3 Lesions on Multiparametric MRI: A Prospective Single-Center Study. Journal of Nuclear Medicine, 65, 555-559. [Google Scholar] [CrossRef] [PubMed]
[34] Guo, S., Kang, F., Ma, S., Jiao, J., Ren, J., Wang, J., et al. (2023) The PRIMARY Score: Diagnostic Performance and Added Value Compared with MRI in Detecting Clinically Significant Prostate Cancer. Clinical Nuclear Medicine, 49, 37-44. [Google Scholar] [CrossRef] [PubMed]
[35] Uslu, H., Şahin, D., İbişoğlu, E. and Tatoğlu, M.T. (2024) PRIMARY Scoring in 68Ga-PSMA PET/CT: Correlation with Prostate Cancer Risk Groups and Its Potential Impact on Active Surveillance. Annals of Nuclear Medicine, 39, 334-341. [Google Scholar] [CrossRef] [PubMed]
[36] Demirbilek, M., Kalender, G., Bıyıkoglu, S., Asa, S., Akkuş, E., Gürses, İ., et al. (2025) External Validation of Nomograms for Predicting Pelvic Lymph Node Metastases in Patients with Prostate Cancer and the Added Value of the Prostate-Specific Membrane Antigen Positron Emission Tomography-Based PRIMARY Score. European Urology Open Science, 82, 170-177. [Google Scholar] [CrossRef] 

为你推荐